MacroGenics, Inc.
MGNXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Apr 20, 2026 | Barclays | $6.00(+73%) | $3.46 | TheFly | |
| May 14, 2025 | Barclays | Peter Lawson | $3.00(+89%) | $1.59 | TheFly |
| Mar 25, 2025 | H.C. Wainwright | $2.00(+12%) | $1.79 | TheFly | |
| Aug 7, 2024 | Stifel Nicolaus | Stephen Willey | $6.00(+78%) | $3.38 | StreetInsider |
| Jul 31, 2024 | JMP Securities | Silvan Tuerkcan | $8.00(+52%) | $5.25 | TheFly |
| Jul 31, 2024 | B.Riley Financial | Mayank Mamtani | $5.00(-5%) | $5.25 | StreetInsider |
| Jul 29, 2024 | Barclays | Peter Lawson | $9.00(+62%) | $5.55 | TheFly |
| May 23, 2024 | BTIG | Kaveri Pohlman | $9.00(+94%) | $4.63 | TheFly |
| May 13, 2024 | H.C. Wainwright | Debjit Chattopadhyay | $4.00(-9%) | $4.38 | StreetInsider |
| May 10, 2024 | Barclays | Peter Lawson | $14.00(-5%) | $14.67 | TheFly |
| May 10, 2024 | BMO Capital | Etzer Darout | $8.00(-45%) | $14.67 | TheFly |
| Apr 4, 2024 | Stifel Nicolaus | Stephen Willey | $29.00(+112%) | $13.67 | StreetInsider |
| Nov 22, 2022 | Guggenheim | Charles Zhu | $12.00(+94%) | $6.18 | StreetInsider |
| Jul 11, 2022 | BTIG | Kaveri Pohlman | $6.00(+69%) | $3.55 | TheFly |
| Jun 16, 2021 | Wedbush | David Nierengarten | $32.00(+53%) | $20.86 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| B. Riley Securities | maintain | Buy | Aug 17, 2026 |
| Barclays | maintain | Overweight | Apr 20, 2026 |
| B. Riley Securities | upgrade | Neutral →Buy | Apr 10, 2026 |
| Barclays | maintain | Overweight | Mar 10, 2026 |
| HC Wainwright & Co. | maintain | Neutral | Nov 3, 2025 |
| Leerink Partners | maintain | Outperform | Aug 15, 2025 |
| B. Riley Securities | maintain | Neutral | May 20, 2025 |
| Barclays | maintain | Overweight | May 14, 2025 |
| Stifel | maintain | Hold | May 14, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Mar 25, 2025 |
| JMP Securities | downgrade | Market Outperform →Market Perform | Nov 7, 2024 |
| HC Wainwright & Co. | maintain | Neutral | Nov 6, 2024 |
| HC Wainwright & Co. | maintain | Neutral | Sep 18, 2024 |
| HC Wainwright & Co. | maintain | Neutral | Aug 21, 2024 |
| Citigroup | maintain | Buy | Aug 15, 2024 |
| BMO Capital | maintain | Market Perform | Aug 7, 2024 |
| HC Wainwright & Co. | maintain | Neutral | Aug 1, 2024 |
| BTIG | downgrade | Buy →Neutral | Aug 1, 2024 |
| JMP Securities | maintain | Market Outperform | Jul 31, 2024 |
| B. Riley Securities | downgrade | Buy →Neutral | Jul 31, 2024 |
| Guggenheim | downgrade | Buy →Neutral | Jul 31, 2024 |
| Barclays | maintain | Overweight | Jul 31, 2024 |
| Barclays | maintain | Overweight | Jul 29, 2024 |
| BTIG | maintain | Buy | May 24, 2024 |
| HC Wainwright & Co. | maintain | Neutral | May 13, 2024 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-0.32| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $0.31 | $-0.08 | $32.8M | $59.1M |
| May 13, 2026 | $-0.58 | $-0.57 | $20.8M | $15.2M |
| Mar 9, 2026 | $-0.22 | $-0.42 | $41.2M | $34.6M |
| Nov 12, 2025 | $0.27 | $-0.48 | $72.8M | $27.8M |
| Aug 14, 2025 | $-0.57 | $-0.59 | $22.2M | $24.4M |
| May 13, 2025 | $-0.65 | $-0.61 | $13.2M | $11.8M |
| Mar 20, 2025 | $-0.25 | $-0.23 | $17.7M | $34.2M |
| Nov 5, 2024 | $0.90 | $0.21 | $110.7M | $32.7M |
News
ROCKVILLE, MD, Nov. 03, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointments of Emil Kuriakose, M.D. and Michael Vasconcelles, M.D.
ROCKVILLE, MD, Oct. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced positive interim data from its ongoing Phase 2 LINNET study evaluating lorigerlimab, a bispecific DART® molecule that targets PD-1 and CTLA-4, in patients with CCGC. These Phase 2 data were presented today at the European Society for Medical Oncology (ESMO) 2026 Congr…
ROCKVILLE, MD, Oct. 23, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced positive interim data from its Phase 1 study evaluating MGC026, a B7-H3-directed antibody-drug conjugate (ADC), in patients with advanced solid tumors. These Phase 1 data were presented today at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid,…
ROCKVILLE, MD, Oct. 15, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the first patient has been dosed in the Phase 1 study of MGC030, a first-in-class antibody-drug conjugate (ADC) directed against an undisclosed target, in patients with advanced solid tumors. “MGC030 demonstrated encouraging antitumor activity in multiple preclin…
Here is how MacroGenics (MGNX) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.
Seeking Alpha welcomed 38 new analysts in September 2026. This article showcases their top picks and investment strategies. Highlighted companies include Qualcomm, Teladoc, and NewLake Capital Partners, as well as the ETF TDAQ, each with a detailed investment thesis. We invite you all to engage with our new contributing analysts, explore their diverse investment theses, and consider following up on the highlighted stock ideas.
ROCKVILLE, MD, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, September 16, 2026, at 9:30 a.m. ET.
Positive risk/reward with MacroGenics trading at a discount to its $327 million cash position or $5.15/share. Differentiated pipeline includes antibody drug conjugates (ADC), T-cell engagers (TCE), and lorigerlimab, with multiple near-term catalysts to drive potential upside. Gilead's recent activity on multiple TCEs and MacroGenics' negative enterprise value suggest partnership is under appreciated & undervalued.
Bank of America Corp DE increased its stake in shares of MacroGenics, Inc. (NASDAQ: MGNX) by 30.7% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 2,401,814 shares of the biopharmaceutical company's stock after purchasing an additional 564,094 shares during the period. Bank of America
Here is how MacroGenics (MGNX) and CareDx (CDNA) have performed compared to their sector so far this year.
The company's HIV franchise is stronger than ever, and it's adding a stable of oncology drugs.
MacroGenics (MGNX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.57 per share a year ago.
ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the quarter ended June 30, 2026, and highlighted its recent corporate and pipeline progress.
ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Gilead Sciences, Inc. has exercised its option to obtain an exclusive license for a preclinical bispecific program under the companies' 2022 collaboration agreement. The option exercise triggers a $10 million payment to MacroGenics.